B. Riley Securities Maintains Buy on Harrow Health, Raises Price Target to $45
Portfolio Pulse from richadhand@benzinga.com
B. Riley Securities analyst Sahil Kazmi maintains a Buy rating on Harrow Health (NASDAQ:HROW) and raises the price target from $42 to $45.
July 20, 2023 | 2:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B. Riley Securities maintains a Buy rating on Harrow Health and raises the price target from $42 to $45, which could positively impact the stock's price.
The raised price target by B. Riley Securities indicates a positive outlook for Harrow Health. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100